Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

14.75
-0.0310-0.21%
Post-market: 14.08-0.6700-4.54%19:59 EST
Volume:7.96M
Turnover:123.59M
Market Cap:228.85M
PE:- -
High:15.93
Open:14.58
Low:13.06
Close:14.78
52wk High:15.93
52wk Low:13.06
Shares:15.52M
Float Shares:11.14M
Volume Ratio:1.25
T/O Rate:71.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-4.9715
ROE:-43.98%
ROA:-26.47%
PB:0.14
PE(LYR):-2.97

Loading ...

Swiss stocks - Factors to watch on October 27

Reuters
·
Oct 27, 2025

Novartis to Acquire Avidity Biosciences for About $12 Billion

Reuters
·
Oct 27, 2025

Dow Jones Top Company Headlines at 9 PM ET: Novartis Agrees to Acquire Avidity Biosciences for $12 Billion | HSBC ...

Dow Jones
·
Oct 27, 2025

PRESS DIGEST- Financial Times - October 27

Reuters
·
Oct 27, 2025

BRIEF-Avidity Biosciences Says Spinco To Be Led By Kathleen Gallagher As Ceo

Reuters
·
Oct 27, 2025

Avidity Biosciences Enters Into Agreement to Be Acquired by Novartis Ag

THOMSON REUTERS
·
Oct 27, 2025

Avidity Biosciences Inc - Spinco to Be Led by Kathleen Gallagher as CEO

THOMSON REUTERS
·
Oct 27, 2025

Novartis to acquire Avidity Biosciences for $12 billion

Reuters
·
Oct 27, 2025

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

GlobeNewswire
·
Oct 27, 2025

Novartis Set to Announce $10Bn Plus Avidity Biosciences Purchase-FT

THOMSON REUTERS
·
Oct 27, 2025

Novartis close to deal to buy Avidity for over $70 per share, Bloomberg says

TIPRANKS
·
Oct 26, 2025

BRIEF-Novartis Said To Near $70-Per-Share-Plus Deal For Avidity-Bloomberg News

Reuters
·
Oct 26, 2025

Novartis Said to Near $70-per-Share-Plus Deal for Avidity-Bloomberg News

THOMSON REUTERS
·
Oct 26, 2025

Avidity Biosciences Chief Medical Officer Steven George Hughes Reports Disposal of Common Shares

Reuters
·
Oct 25, 2025

CSPC PHARMA (01093): SYH2061 Injection (Dual-Chain Small Interfering RNA Drug) Approved for Clinical Trials in China

Stock News
·
Oct 24, 2025

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

GlobeNewswire
·
Oct 20, 2025

Avidity Biosciences Inc. Chief Human Resources Officer Teresa McCarthy Reports Disposal of Common Shares

Reuters
·
Oct 18, 2025

Avidity Biosciences Delays Biologics License Application

TIPRANKS
·
Oct 14, 2025

Avidity Biosciences Showcases Advancements in RNA Therapeutics and Progress Toward Commercializing Rare Neuromuscular Disease Treatments

Reuters
·
Oct 14, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv

Reuters
·
Oct 14, 2025